Cytotoxic T lymphocyte (CTL) responses to vaccinia virus (VV) were studied in human subjects receiving smallpox vaccine by dermal scarification. After in vitro restimulation with VV, peripheral blood mononuclear cells (PBMCs) from three of six vaccinated subjects killed virus-infected target cells. W-specific, HLArestricted CTL activity was mediated primarily by CD8 + cells, although low levels of lytic activity by CD4 + cells were observed in some experiments. Two of the three responders had no history of exposure to VV prior to vaccination, whereas all three non-responders were vaccinated against smallpox during childhood. PBMCs from an additional three subjects who had received smallpox vaccine at least 20 years previously were negative for CTL activity. These data suggest that the duration of memory CTL populations against W in the peripheral blood is limited, and that pre-existing immunity to VV may interfere with boosting of the CTL response upon revaccination.
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The design of vaccines that will prime virus-specific class I major histocompatibility complex (MHC)-restricted T lymphocytes is complicated by the requirement for processing of antigen within the cytoplasm or endoplasmic reticulum (Morrison et al., 1986; Moore et al., 1988; Germain, 1986) . Recombinant viruses deliver antigens efficiently into the class I antigen presentation pathway (Bennink & Yewdell, 1990; Moss, 1991) , and thus have been proposed as vectors for vaccine delivery in humans. Infection of experimental animals with recombinant vaccinia virus (VV) vectors elicits cytotoxic T lymphocyte (CTL) populations that recognize VV antigens as well as heterologous protein(s) encoded by the virus (Bennink & Yewdell, 1990) . However, attempts to detect class I MHC-restricted, VV-specific CTL in humans immunized against smallpox have been unsuccessful, even after revaccination with the virus (Perrin et aI., 1977; Graham et al., 1991) . These data suggested that recombinant VV vectors may have a limited ability to prime CTL responses in humans (Graham et al., 1991) .
To gain an understanding of factors that influence priming and detection of anti-VV CTLs in humans, we undertook a study of virus-specific CTL activity in 10 laboratory staff volunteers. Smallpox vaccination is currently indicated for laboratory workers directly involved with orthopoxviruses such as VV (Anonymous, 1980) . Accordingly, subjects 1 to 6 who work with recombinant VV vectors were immunized with 0.2 ml of dried smallpox vaccine (Dryvax, Wyeth) by dermal scarification (Table 1) . Vaccine takes were confirmed by visual examination of the inoculation site. Four control subjects (7 to 10) who do not use recombinant VV vectors were not vaccinated.
To generate VV-specific CTLs, peripheral blood mononuclear cells (PBMCs) from study subjects were enriched on Ficoll-Hypaque gradients and washed three times in PBS. PBMCs were then infected with VV (strain WR) at a multiplicity of 1 for 60 min. After one wash, 2 × 10 ~ cells/ml were cultured in 1.5 ml of RPMI 1640 medium supplemented with 10 % heat-inactivated fetal calf serum (FCS; Hyclone) and antibiotics in 24-well tissue culture plates (Costar) for 5 to 7 days. Proliferative responses were observed when PBMCs from vaccinated subjects were cultured with live VV under these conditions (data not shown). Cell viability in the cultures was routinely 60 to 70 % after 5 to 7 days of culture, as assessed by trypan blue exclusion. Cytotoxic activity was assessed against virus-infected target cells in a standard 51Cr release assay (Brunner et al., 1968) . Where indicated, CD8 + and CD4 + cells were enriched from a fraction of the PBMCs immediately before addition to the 51Cr release assay. Lymphocyte populations were purified using magnetic beads coupled to anti-CD8 or -CD4 antibodies as described (Walker et al., 1991) , and were routinely greater than 95 % pure as assessed by flow cytometry.
Target cells for the CTL assays were Epstein-Barr virus-immortalized lymphoblastoid cell lines (LCLs) generated by culture of PBMCs from study subjects with 0001-1253 © 1993 SGM supernatant from the B95-8 cell line. They were infected with VV or herpes simplex virus type 1 (HSV-1) (strain Patton) at an m.o.i, of 10 for 60 rain, washed, and then cultured overnight prior to ~lCr labelling. LCLs are susceptible to lysis by HSV-specific, class I MHCrestricted CTL clonal cell lines when infected with HSV-1 under these conditions (Tigges et aI., 1992) . Cytotoxic activity by unseparated and CD8+-enriched PBMCs was evaluated in a 4 h 51Cr release assay (Table  1) . Data shown are for an effector:target cell ratio of 50:1, but similar results were obtained at ratios of 10:1 and 2:1. Unseparated PBMCs from all 10 subjects demonstrated low or undetectable levels of lysis against uninfected autologous target cells (Table 1) . VV-infected target cells were killed by unseparated PBMC from four of six vaccinated subjects (Table 1 , subjects 1 to 4). However VV-infected allogeneic targets mismatched at all HLA class I A, B and C alleles were also lysed (Table  1) . Previous studies have also documented that PBMCs from recent vaccinees efficiently lyse histoincompatible, VV-infected target cells (Graham e t al., 1991) . This could reflect generation of lymphokine-activated killer cells in these cultures. Significantly, class I MHC-restricted cytotoxic activity was observed when enriched CD8 + cells were tested; VV-infected autologous but not allogeneic target cells were lysed by CD8 + cells isolated from the PBMCs of subjects 1 to 3. PBMCs from subject 4 did not contain class I MHC-restricted CTL activity in the CD8 + cell subset. Neither unseparated nor CD8 +-enriched PBMCs from the four non-vaccinated subjects lysed the VV-infected target cells in an MHC-restricted manner (Table 1) .
To characterize further the specificity of this cytotoxic response, PBMCs from subjects 1 and 2 were restimulated with VV and evaluated for the ability to lyse autologous target cells infected with VV or HSV-1. Two representative experiments are shown in Table 2 . Unseparated PBMCs efficiently lysed autologous VVinfected targets, but elevated levels of lysis were often observed against histoincompatible targets infected with VV and/or autologous targets infected with HSV-1. However, CD8 + effector cells enriched from the PBMCs preferentially lysed autologous VV-infected but not uninfected or HSV-l-infected target cells, and thus are virus-specific, class I MHC-restricted CTLs.
Killing of VV-infected target cells was occasionally observed in the CD4 + cell fraction (Table 2 , experiment 1). This response was not characterized for class II MHC restriction, but appeared to be virus-specific as autologous targets infected with HSV-1 were not lysed. This CD4 + cell-mediated cytotoxic activity is consistent with observations by Littaua et al. (1992) , who recently described VV-specific, class II HLA-restricted CD4 + cells in the PBMCs of a healthy recipient of smallpox vaccine after the cells were restimulated in vitro with u.v.-inactivated VV.
Studies in mice (Rooney et al., 1988) and humans (Cooney et al., 1991) have demonstrated that pre- existing immunity to VV may inhibit priming of T cell responses upon re-exposure to the virus. In the human studies, VV-seronegative vaccinees receiving a recombinant vaccinia virus expressing the gpl60 envelope protein of human immunodeficiency virus had strong proliferative T helper cell responses to gpl60, whereas weak or undetectable responses were observed in subjects
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who had serum antibodies to VV prior to vaccination (Cooney et al., 1991) . To assess the effect of pre-existing immunity on boosting of the anti-VV CTL response, we used a medical questionnaire to obtain a history of smallpox vaccination. The results are shown in Table 3 . Seven of the 10 subjects reported childhood smallpox immunization at least 20 years previously. It is noteworthy that two of the three subjects with CTL activity against VV had not received childhood smallpox vaccination because universal immunization had been discontinued by the time the recommended age for vaccination was reached (subject 1) or medical contraindication (subject 2). It is not clear whether preexisting immunity to VV completely blocked secondary boosting of virus-specific CD8 + cell activity in the nonresponder subjects (Table 1 , subjects 4 to 6) after revaccination. It is possible that limited replication of VV in immune individuals could restrict the response of virus-specific T cells to draining lymph nodes, or induce a transient CTL response to VV that can be detected in peripheral blood for a only a brief period immediately following revaccination. CTL responses to VV have not been observed in vaccinated humans when freshly isolated PBMCs were tested directly (Perrin et al., 1977; Graham et al., 1991) , or after a period of in vitro restimulation with viral antigen (Graham et al., 1991) . In addition to pre-existing immunity, there are two factors that could determine whether VV-specific CTL responses are detected in immune individuals. First, the results reported here were obtained by restimulation of PBMCs with live VV, rather than u.v.-inactivated virus preparations used in previous studies (Graham et al., 1991; Littaua et al., 1992) . Live virus may provide a stronger stimulus for CD8 + cells, given the importance of cytoplasmic processing for efficient class I MHC presentation of viral antigens (Morrison et al., 1986; Germain, 1986) . Further studies are required to assess the status of virus infection in these cultures, and to characterize the target cell(s) capable of supporting VV replication. Second, PBMCs depleted of CD4 + and CD8 + cells were often enriched in non-specific lytic activity directed against MHC-mismatched and HSV-1-infected target cells (Table 2) . Thus, enrichment of CD8 ÷ effector cells may eliminate nonspecific cytotoxic activity that masks the virus-specific, HLA-restricted CTL response.
PBMCs from three subjects (7, 8 and 9) vaccinated against smallpox more than 20 years previously did not lyse VV-infected targets ( (McMichael et at., 1983) . In contrast, CTL responses can be detected against viruses that establish latent or persistent infections, such as the herpesviruses (Yasukawa et al., 1989; Hickling et al., 1986; Rickinson et al., 1981) or human retroviruses (Walker & Plata, 1990; Kannagi et al., 1983; Mitsuya et at., 1983) . Thus, the frequency of anti-VV CD8 + cells could drop to undetectable levels in the absence of periodic re-exposure to viral antigen through reinfection or reactivation of latent viruses. Alternatively, memory CD8 + CTLs directed against VV may eventually be sequestered in lymph nodes and therefore are not detectable in the peripheral blood.
The results of this study demonstrate for the first time that VV can elicit a cytotoxic response by HLArestricted, virus-specific CD8 + lymphocytes. Furthermore, the methods described here could be used to define the duration of memory anti-VV CTL populations in prospective studies of humans receiving smallpox vaccine. This information could provide important insights into the design and use of recombinant VV vectors for priming and boosting of protective CD8 + T cell responses to other pathogens.
